Section Arrow
Quote
CPIX.NASDAQ
- Cumberland Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/07 08:41 EST
Pre Market
Last
 2.15
-0.04 (-1.83%)
Bid
2.14
Ask
3.14
High 2.15 
Low 2.15 
Volume 6 
Regular Hours
Last
 2.19
-0.14 (-6.01%)
Day High 
2.3278 
Prev. Close
2.33 
1-M High
3.6884 
Volume 
62.28K 
Bid
2.14
Ask
3.14
Day Low
2.18 
Open
2.27 
1-M Low
2.29 
Market Cap 
34.86M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.07 
20-SMA 3.27 
50-SMA 3.3 
52-W High 7.25 
52-W Low 1.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.22/--
Enterprise Value
49.97M
Balance Sheet
Book Value Per Share
1.87
Cash Flow
Cash Flow Yield
0.21
Income Statement
Total Revenue
37.87M
Operating Revenue Per Share
2.72
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health41.52-2.21-5.05%83.3PE
Pre Market 40.64 -0.88 -2.12%
TLRYTilray Brands1.21-0.07-5.47%-- 
Pre Market 1.21 0 0.00%
TEVATeva Pharmaceutical Industries Limited24.46-0.14-0.57%-- 
Pre Market 24.15 -0.31 -1.27%
CGCCanopy Growth Corp1.09-0.05-4.39%-- 
Pre Market 1.29 +0.2 +18.35%
VTRSViatris10.11-0.64-5.95%227.2PE
Pre Market 10.1 -0.01 -0.10%
Quotes are at least 15-min delayed：2025/11/07 08:41 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.